To conclude, all these studies indicate that the LKB1/AMPK downstream pathways passing through mTOR and controlling cell growth is an attractive candidate for targeted therapies for LKB1-mutated NSCLC (Figure 2). This evidence concerns the gene STK11 and non-small cell lung carcinoma.